Literature DB >> 23891753

Inhibition of microRNA122 decreases SREBP1 expression by modulating suppressor of cytokine signaling 3 expression.

Chikako Shibata1, Takahiro Kishikawa, Motoyuki Otsuka, Motoko Ohno, Takeshi Yoshikawa, Akemi Takata, Haruhiko Yoshida, Kazuhiko Koike.   

Abstract

While inhibition of microRNA122 (miR122) function in vivo results in reduced serum cholesterol and fatty acid levels, the molecular mechanisms underlying the link between miR122 function and lipid metabolism remains unclear. Because the expression of SREBP1, a central transcription factor involved in lipid metabolism, is known to be increased by suppressor of cytokine signaling 3 (SOCS3) expression, and because we previously found that SOCS3 expression is regulated by miR122, in this study, we examined the correlation between miR122 status and the expression levels of SOCS3 and SREBP1. SREBP1 expression decreased when SOCS3 expression was reduced by miR122 silencing in vitro. Conversely, SREBP1 expression in miR122-silenced cells was restored by enforced expression of SOCS3. Such correlations were observed in human liver tissues with different miR122 expression levels. These signaling links may explain one of the molecular mechanisms linking inhibition of miR122 function or decreased expression of miR122 to decreased fatty acid and cholesterol levels, in the inhibition of miR122 function, or in pathological status in chronic liver diseases.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Expression regulation; Liver; SOCS3; SREBP; microRNA

Mesh:

Substances:

Year:  2013        PMID: 23891753     DOI: 10.1016/j.bbrc.2013.07.064

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Micro RNAs in the development of non-alcoholic fatty liver disease.

Authors:  Glenn S Gerhard; Johanna K DiStefano
Journal:  World J Hepatol       Date:  2015-02-27

2.  Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3.

Authors:  Ketti G Oliveira; Fernanda M Malta; Ana C S S Nastri; Azzo Widman; Paola L Faria; Rúbia A F Santana; Venâncio A F Alves; Flair J Carrilho; João R R Pinho
Journal:  Med Microbiol Immunol       Date:  2015-08-14       Impact factor: 3.402

3.  Are miRNA-103, miRNA-107 and miRNA-122 Involved in the Prevention of Liver Steatosis Induced by Resveratrol?

Authors:  Ana Gracia; Alfredo Fernández-Quintela; Jonatan Miranda; Itziar Eseberri; Marcela González; María P Portillo
Journal:  Nutrients       Date:  2017-04-04       Impact factor: 5.717

4.  Mechanistic roles of microRNAs in hepatocarcinogenesis: A study of thioacetamide with multiple doses and time-points of rats.

Authors:  Harsh Dweep; Yuji Morikawa; Binsheng Gong; Jian Yan; Zhichao Liu; Tao Chen; Halil Bisgin; Wen Zou; Huixiao Hong; Tieliu Shi; Ping Gong; Christina Castro; Takeki Uehara; Yuping Wang; Weida Tong
Journal:  Sci Rep       Date:  2017-06-08       Impact factor: 4.379

5.  miR-29a Promotes Lipid Droplet and Triglyceride Formation in HCV Infection by Inducing Expression of SREBP-1c and CAV1.

Authors:  Mennatallah Mamdouh Mahdy; Nada Magdy El-Ekiaby; Rana Mahmoud Hashish; Radwa Ayman Salah; Rasha Sayed Hanafi; Hassan Mohamed Azzazy; Ahmed Ihab Abdelaziz
Journal:  J Clin Transl Hepatol       Date:  2016-12-26

6.  High Fat Diet-Induced miR-122 Regulates Lipid Metabolism and Fat Deposition in Genetically Improved Farmed Tilapia (GIFT, Oreochromis niloticus) Liver.

Authors:  Jun Qiang; Yi Fan Tao; Jing Wen Bao; De Ju Chen; Hong Xia Li; Jie He; Pao Xu
Journal:  Front Physiol       Date:  2018-10-05       Impact factor: 4.566

7.  Ascorbate protects liver from metabolic disorder through inhibition of lipogenesis and suppressor of cytokine signaling 3 (SOCS3).

Authors:  Yingying Xu; Yuhang Wu; Yue Xiong; Jiawang Tao; Tingcai Pan; Shenglin Tan; Ge Gao; Yan Chen; Nasir Abbas; Anteneh Getachew; Yuanqi Zhuang; Kai You; Fan Yang; Yin-Xiong Li
Journal:  Nutr Metab (Lond)       Date:  2020-03-04       Impact factor: 4.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.